Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Cash & Current Investments data on file, last reported at $202.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 40.66% year-over-year to $202.3 million; the trailing twelve-month figure through Mar 2026 stood at $202.3 million (down 40.66% YoY), and the FY2025 full-year result was $263.8 million, down 29.57% from the prior year.
• Cash & Current Investments fell to $202.3 million in Q1 2026, from $263.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $501.5 million in Q1 2023 to a low of $202.3 million in Q1 2026.
• A 5-year average of $389.7 million and a median of $388.3 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments rose 15.24% in 2023 and sank 40.66% in 2026, its largest moves.
• Tracing VNDA's Cash & Current Investments over 5 years: stood at $466.9 million in 2022, then declined by 16.83% to $388.3 million in 2023, then fell by 3.51% to $374.6 million in 2024, then retreated by 29.57% to $263.8 million in 2025, then retreated by 23.32% to $202.3 million in 2026.
• Business Quant data shows VNDA's Cash & Current Investments at $202.3 million in Q1 2026, $263.8 million in Q4 2025, and $293.8 million in Q3 2025.